Frontage Welcomes Glenn Washer, BSc, DABT as Executive Vice President, Global Safety & Toxicology Services

EXTON, Pa., March 10, 2020 /PRNewswire/ — Frontage Laboratories is pleased to announce that Glenn Washer, BSc, DABT has joined Frontage as our Executive Vice President, Global Safety & Toxicology Services.  Glenn will report directly to Dr. Song Li, CEO.

Glenn has more than 35 years of experience in increasingly responsible roles within the realm of Safety/Toxicology at various companies.  In his most recent position, Glenn served as the President, Charles River Laboratories, Montreal, Canada and as the Corporate Senior Vice President, for Charles River’s North America Safety Assessment sites.  He brings a wealth of knowledge and experience to his new role, including extensive executive management experience and P&L responsibility in regulated contract research and biopharmaceuticals industries with emphasis on multi-site, multi-national CRO management, research & development.  Glenn has in-depth knowledge and experience in operations management, M&A due diligence, integration of new acquisitions, organizational restructuring, and strategic planning.

Glenn will be responsible for the overall leadership and the strategic global growth of the Safety/Toxicology business at Frontage Laboratories. 

“We’re very excited to welcome Mr. Glenn Washer onboard as our Executive Vice President, Global Safety and Toxicology”, said Dr. Song Li, CEO of Frontage Laboratories, “Mr. Washer’s experience in preclinical drug development, safety and toxicology, translational science and medicine makes him ideally suited to taking this role. We have confidence in his leadership to strengthen Frontage’s capabilities and capacities in preclinical development globally”.

Mr. Washer commented: “I am very excited to be joining the impressive team at Frontage.  Their leadership team’s dedication to the highest levels of scientific rigor, quality, customer service, and employee development give me great confidence that we share the same values and vision.  I look forward to the opportunity to contribute to the continued growth of this exceptional global organization.”

For more information: https://www.frontagelab.com/about/news-item/frontage-welcomes-glenn-washer/

Contact: Shannon C. Ryan
Sryan@frontagelab.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/frontage-welcomes-glenn-washer-bsc-dabt-as-executive-vice-president-global-safety–toxicology-services-301020707.html

SOURCE Frontage Laboratories, Inc.

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

6 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

7 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

7 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

8 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago